SU16f is a potent and selective PDGFRβ inhibitor (IC50 = 10 nM), with weaker activity against PDGFRα (IC50 = 140 nM) and PDGFR1 (IC50 = 2.29 μM). It inhibits PDGFRβ activation, thereby blocking the promoting effects of gastric cancer-derived mesenchymal stem cell (GC-MSC) conditioned medium (CM) on gastric cancer cell proliferation and migration. SU16f pretreatment upregulates E-cadherin and downregulates N-cadherin, Vimentin, and α-SMA expression, indicating suppression of epithelial-mesenchymal transition (EMT). Additionally, it modulates apoptosis-related proteins by downregulating p-AKT, Bcl-xL, and Bcl-2, and upregulating Bax in SGC-7901 gastric cancer cells. It is used in vitro to study PDGFR signaling, cancer cell proliferation, migration, EMT, and apoptosis in co-culture systems involving GC-MSCs and gastric cancer cells.